Stocktoria
GYRE THERAPEUTICS, INC. GYRE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2006-04-12
GYRE THERAPEUTICS, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | 96.3% | 95.9% | 95.3% | — |
| Operating margin | 9.9% | 15.3% | -59.3% | 9.0% | -1197.8% |
| Net margin | 8.5% | 16.9% | -75.3% | 4.2% | -1198.3% |
| FCF margin | -0.2% | -5.6% | 15.3% | 5.6% | -1152.8% |
| Return on assets | 5.9% | 14.3% | -73.3% | 5.1% | -158.0% |
| Return on equity | 6.9% | 18.2% | 540.1% | 6.0% | -147.9% |
| Current ratio | 5.60 | 3.32 | 2.85 | 4.06 | 3.63 |
| Revenue growth | 10.2% | -6.8% | 10.9% | 1294.0% | -65.0% |
Source: SEC EDGAR filings · CIK 0001124105 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.